Copd Exacerbation and Pulmonary Hypertension Trial

• Status: Recruiting
• Trial end date: 2025-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial will investigate whether patiens admitted with an acute exacerbation of chronic obstructive lung disease and pulmonary hypertension will benefit from a targeted pharmacological treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
• Treatments: Sildenafil Citrate

Criteria

Inclusion Criteria:

• COPD verified by specialist and spirometry

• Admitted with the diagnosis "acute exacerbation of COPD"

• TR-gradient ≥40 mmHg verified by specialist and echocardiography

• Informed consent

Exclusion Criteria:

• Known pulmonal hypertension

• Known heart disease which affects the pump function of the heart

• Men <40 years

• Women <55 years

• Not-menopauseal women <55 years (Menopause is defined as no menstruation within 12 months.)

• Severe mental illness which significantly complicates cooperation

• Severe language difficulties which significantly complicates cooperation

• known allergy to Sildenafil

• Sildenafil consumption ≥50 mg / week due to other indications